Alx Oncology Holdings (ALXO) Depreciation & Amortization (CF) (2019 - 2026)
Alx Oncology Holdings' Depreciation & Amortization (CF) history spans 5 years, with the latest figure at $207000.0 for Q4 2023.
- On a quarterly basis, Depreciation & Amortization (CF) rose 97.14% to $207000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $836000.0, a 144.44% increase, with the full-year FY2025 number at $706000.0, down 19.04% from a year prior.
- Depreciation & Amortization (CF) hit $207000.0 in Q4 2023 for Alx Oncology Holdings, down from $209000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for ALXO hit a ceiling of $213000.0 in Q1 2023 and a floor of $5000.0 in Q3 2020.
- Historically, Depreciation & Amortization (CF) has averaged $91888.9 across 5 years, with a median of $89500.0 in 2022.
- Biggest five-year swings in Depreciation & Amortization (CF): plummeted 95.58% in 2021 and later surged 1483.33% in 2022.
- Tracing ALXO's Depreciation & Amortization (CF) over 5 years: stood at $112000.0 in 2019, then plummeted by 95.54% to $5000.0 in 2020, then surged by 580.0% to $34000.0 in 2021, then skyrocketed by 208.82% to $105000.0 in 2022, then soared by 97.14% to $207000.0 in 2023.
- Business Quant data shows Depreciation & Amortization (CF) for ALXO at $207000.0 in Q4 2023, $209000.0 in Q3 2023, and $207000.0 in Q2 2023.